



# Paracetamol in Older People: Towards Evidence-Based Dosing?

Paola Mian<sup>1</sup> · Karel Allegaert<sup>1,2,3</sup> · Isabel Spriet<sup>4,5</sup> · Dick Tibboel<sup>1</sup> · Mirko Petrovic<sup>6</sup>

Published online: 19 June 2018  
© The Author(s) 2018

## Abstract

Paracetamol is the most commonly used analgesic in older people, and is mainly dosed according to empirical dosing guidelines. However, the pharmacokinetics and thereby the effects of paracetamol can be influenced by physiological changes occurring with ageing. To investigate the steps needed to reach more evidence-based paracetamol dosing regimens in older people, we applied the concepts used in the paediatric study decision tree. A search was performed to retrieve studies on paracetamol pharmacokinetics and safety in older people (> 60 years) or studies that performed a (sub) analysis of pharmacokinetics and/or safety in older people. Of 6088 articles identified, 259 articles were retained after title and abstract screening. Further abstract and full-text screening identified 27 studies, of which 20 described pharmacokinetics and seven safety. These studies revealed no changes in absorption with ageing. A decreased (3.9–22.9%) volume of distribution ( $V_d$ ) in robust older subjects and a further decreased  $V_d$  (20.3%) in frail older compared with younger subjects was apparent. Like  $V_d$ , age and frailty decreased paracetamol clearance (29–45.7 and 37.5%) compared with younger subjects. Due to limited and heterogeneous evidence, it was difficult to draw firm and meaningful conclusions on changed risk for paracetamol safety in older people. This review is a first step towards bridging knowledge gaps to move to evidence-based paracetamol dosing in older subjects. Remaining knowledge gaps are safety when using therapeutic dosages, pharmacokinetics changes in frail older people, and to what extent changes in paracetamol pharmacokinetics should lead to a change in dosage in frail and robust older people.

---

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s40266-018-0559-x>) contains supplementary material, which is available to authorized users.

---

✉ Paola Mian  
p.mian@erasmusmc.nl

- <sup>1</sup> Intensive Care and Department of Paediatric Surgery, Erasmus MC, Sophia Children's Hospital, Room NA-1723, Wytemaweg 80, Rotterdam 3015 CN, The Netherlands
- <sup>2</sup> Division of Neonatology, Department of Pediatrics, Erasmus MC, Sophia Children's Hospital, Rotterdam, The Netherlands
- <sup>3</sup> Department of Development and Regeneration, KU Leuven, Louvain, Belgium
- <sup>4</sup> Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Louvain, Belgium
- <sup>5</sup> Pharmacy Department, University Hospital Leuven, Louvain, Belgium
- <sup>6</sup> Department of Geriatrics, Ghent University Hospital, Ghent, Belgium

## Key Points

Paracetamol is the most commonly used analgesic in older people, and is mainly dosed according to clinical experience, expert opinions or extrapolated from studies in younger adults. However, physiological changes occur with increasing age and can thereby influence the pharmacokinetics and effect of paracetamol.

Based on different non-compartmental pharmacokinetic paracetamol studies, decreases in clearance (CL) and volume of distribution ( $V_d$ ) between young adults and robust older subjects have been reported, with further decreases of CL and  $V_d$  in frail older people. Consequently, the question should no longer be if these changes are statistically significant, but whether the difference in pharmacokinetic parameters in older subjects is clinically relevant enough for dose adaptation.

Based on the—albeit limited—observations retrieved in our search, there is no evidence to support a higher incidence of hepatotoxicity of paracetamol in normal dosages in older subjects. Overall, due to limited and heterogeneous evidence, it was difficult to draw firm and meaningful conclusions on changed risk for paracetamol safety in older people.

Remaining knowledge gaps are safety when using therapeutic dosages, pharmacokinetic changes in frail older people, and to what extent the changes in paracetamol pharmacokinetics should lead to an adaptation in dosing in both frail and robust older people.

## 1 Introduction


Worldwide, 901 million people were aged 60 years or older in 2015 [1]. This older population has increased by 48% from 2000 and will continue to increase [2]. Obviously, diseases become more prevalent with advanced age and with them the use of multiple medications [2, 3]. The use of medication by older people has increased 3- to 5-fold over the past decades and is expected to rise even more [4].

Pain (mostly chronic) is one of the most common problems among older people and a very common indication for pharmacotherapy [5, 6]. As older people undergo surgery four times more often than younger populations [7], they arguably also have a larger probability of acute pain. Thus, effective pain management is obviously needed [8]. Unfortunately, older people's pain is often underreported, underestimated and undertreated [9]. Ineffective management is partly caused by older people's changed physiology; that

is, increased total body fat and decreased kidney function [10, 11]. Furthermore, drug dosing is often inappropriate because older people (including those with multiple comorbidities) are hardly ever included in clinical trials [10, 12]. Several guidelines and consensus papers have been written to overcome this problem, but these are mostly based on clinical experience, expert opinions and current treatment extrapolated from studies in younger adults [9].

Paracetamol (acetaminophen, APAP) is the most used analgesic in older people; for example, to treat musculoskeletal or low back pain [12]. Paracetamol is extensively metabolised by different pathways in the liver (Fig. 1) [13]. In young adults, paracetamol is metabolised to paracetamol-glucuronide and paracetamol-sulphate as main metabolites (85–90%) [14–16]. Five percent is excreted as unchanged paracetamol in urine and 5–10% is oxidised by cytochrome P450 (CYP450), primarily by CYP2E1, to a toxic metabolite, N-acetyl-p-benzoquinone-imine (NAPQI) [17]. At therapeutic doses, NAPQI is subsequently neutralised by glutathione and is excreted as cysteine and mercapturate metabolites by the renal route. However, glutathione can be depleted, such as in case of an overdose or malnourished state, resulting in acute liver damage [18, 19].

Although several guidelines provide dosing advice (Table 1), there is no specific focus on older people, either robust or frail, and with or without comorbidity. The physiological changes associated with ageing potentially influences the pharmacokinetics of paracetamol and thereby its effects [20]. Furthermore, to have a better evidence base for dosing, safety should be considered given the potential



**Fig. 1** Overview of paracetamol metabolism. *CYP2E1* cytochrome P450 2, *GSH* glutathione, *NAPQI* N-acetyl-p-benzoquinone-imine, *SULT* sulphotransferase, *UGT* UDP-glucuronosyltransferase

**Table 1** Dosing suggestions from guidelines and labels for paracetamol for older people

|                                       | Dosing advice  | Maximum daily dose             | Remark   |
|---------------------------------------|--|--------------------------------|--|
| Guideline or consensus                |  |                                |  |
| American Geriatrics Society [62]      | 325–500 mg every 4 h or 500–1000 mg every 6 h                                | 4000 mg                        | Reduce maximum dose 50–75% in patients with hepatic insufficiency or history of alcohol abuse  |
| British Geriatrics Society [63]       |  | 4000 mg                        |  |
| Labels for intravenous administration |  |                                |  |
| OFIRMEV (USA) [64]                    |  |                                |  |
| Adults ≥ 50 kg                        | 1000 mg every 6 h or 650 mg every 4 h  | 4000 mg                        |  |
| Adults < 50 kg                        | 15 mg/kg every 6 h or 12 mg/kg every 4 h                                     | 75 mg/kg                       |  |
| Perfalgan (EU) [65]                   |  |                                |  |
| Adults > 50 kg                        | 1000 mg<br>Minimum interval between each administration must be at least 4 h | 4000 mg                        | Minimal interval between each administration must be at least 6 h for patients with severe renal insufficiency<br>No more than 4 doses to be given in 24 h<br>Maximum daily dose is 3000 mg for patients > 50 kg with additional risk factors for hepatotoxicity |
| Adults ≤ 50 kg                        | 15 mg/kg   | 60 mg/kg not exceeding 3000 mg |  |
| Labels for oral administration        |  |                                |  |
| Tylenol® (USA)                        |  |                                |  |
| Adults                                | 1000 mg every 6 h  | 3000 mg                        |  |
| Panadol® (EU) [66]                    |  |                                |  |
| Adults > 15 years of age and > 55 kg  | 500–1000 mg, every 4–6 h   | 3000 mg                        |  |
| Adults ≤ 55 kg                        | 500 mg, every 4–6 h  | 3000 mg                        |  |

USA United States of America, EU European Union


toxicity of one of the metabolites. Therefore, for this special population, the key question is *what dose should we consider as optimal?*

For the paediatric population, the United States Food and Drug Administration (FDA) and the European Medicine Agency (EMA) proposed a study decision tree to guide drug development and to generate evidence-based dosing [21, 22]. This decision tree can also be applied in other special populations in which physiological changes [20] occur, such as older people. This paediatric study decision tree consists of an assumption-based framework to determine the type of information needed for labelling, or to support more evidence-based dosing of existing drugs [21, 22]. It enables extrapolation of efficacy, from (healthy) young adult data or data in other subpopulations. The assumptions to be considered are similarity in disease progression, response to intervention and exposure–response relationships in the paediatric population and adults. Pharmacokinetics, pharmacodynamics and/or

safety studies have to be conducted, taking into account the presence or absence of these similarities [21, 22].

When applying this study decision tree in both robust and frail older people (Fig. 2), it seems reasonable to assume similarities in pain (e.g. postoperative, traumatic, chronic) relief response between younger adults and older people following similar paracetamol exposure. This is, however, an assumption not yet supported by robust data. Based on this decision tree, pharmacokinetics and safety studies are pivotal to reach safe and effective analgesic use of paracetamol in both robust and frail older people (Fig. 2 grey boxes). Applying this study decision tree in older people minimises the exposure of older people in clinical trials and facilitates more timely access to effective and safe medicines, or at least pharmacokinetics and factors influencing pharmacokinetics (e.g. covariates) are a prerequisite to explore potential age-dependent differences in pain relief response following paracetamol exposure.

**Fig. 2** Paediatric study decision tree [21, 22] applied to paracetamol in older people (grey boxes apply). *PD* pharmacodynamics, *PK* pharmacokinetics



In this review, we applied the study decision tree using paracetamol in (a) robust older people and (b) geriatric patients (i.e. with frailty, multi-morbidity, polypharmacy), and aimed to inventory what is already known of pharmacokinetics and safety. Our ultimate goal is to investigate which steps are needed to reach evidence-based dosing of paracetamol in this heterogeneous and growing population.

## 2 Methods

### 2.1 Inclusion Criteria

A search was performed to retrieve studies on paracetamol pharmacokinetics and safety in older people or studies that performed a sub-analysis of pharmacokinetics and safety in older people. Studies on both paracetamol and propacetamol were considered, as propacetamol (no longer marketed in Europe) is a prodrug of paracetamol that is rapidly hydrolysed (propacetamol 1 g to paracetamol 0.5 g) by plasma esterase [23]. Paracetamol by both intravenous and enteral (oral, rectal) routes of administration were considered for inclusion. Only studies including paracetamol in therapeutic dosages were included. Participants were both robust older people and geriatric patients (i.e. with frailty, multi-morbidity, polypharmacy). Older people included in

the analysis were defined as those > 60 years of age [1]. To pinpoint the potential influence of ageing, studies comparing pharmacokinetics and/or safety of older people with that of younger subjects were included. The data of younger subjects were also extracted to enable comparison. However, we have not performed a fully systematic search on data in people < 60 years. Eligible studies were randomised controlled trials or observational studies.

### 2.2 Search Strategy

#### 2.2.1 Electronic Resources

A search was conducted in Embase, Medline Ovid, Web of Science, Scopus, Cochrane Library, PubMed Publisher, CINAHL EBSCOhost and Google Scholar on 5 October 2017. No language restrictions were made. Keywords were paracetamol/acetaminophen/propacetamol, pharmacokinetics, pharmacodynamics, drug safety, elderly, frail, ageing. The search strategy is detailed in Appendix I (see electronic supplementary material [ESM]).

#### 2.2.2 Other Resources

References of included studies were checked for relevant articles.

### 2.3 Study Selection and Data Extraction

Titles and abstracts of retrieved citations were screened for relevance by PM, after which full texts of potentially eligible studies were obtained. Studies not meeting the inclusion criteria were excluded. In case of doubt, KA was consulted. PM extracted the following data from each pharmacokinetics or safety study: patient population and study design characteristics such as population, number of patients, age, weight, condition (drugs, medical disorders), paracetamol drug information (dose, form), number of samples and study duration. For pharmacokinetics studies, ageing-related changes in the pharmacokinetics of paracetamol (and its metabolites) were extracted, such as clearance and volume of distribution with or without comparison with younger subjects. For safety studies, safety markers (i.e. gastrointestinal, hepatic and renal) were extracted with or without comparison with younger subjects.


## 3 Results

### 3.1 Study Selection and Data Extraction

A total of 6088 potentially relevant studies were identified, four of which were obtained through reference checking or manual searching. After removal of duplicates, titles and abstracts of 4864 were screened for potential relevancy. Full texts were obtained for 259 studies, of which 232 were excluded. The most important reason for exclusion was simultaneous analyses of results of young and older patients without subpopulation data, or inclusion of only younger subjects. Consequently, 27 studies were included, of which 20 were pharmacokinetics studies and seven were safety studies. Figure 3 outlines the selection flow chart.

Paracetamol pharmacokinetics will be discussed first according to the ADME (absorption, distribution,

**Fig. 3** Flowchart of the screening process



PK= pharmacokinetics, N= number

metabolism, elimination) sequence. Thereafter, safety data will be discussed per type of adverse event arising from the search, namely hepato-, nephro- and gastrointestinal toxicity.

## 3.2 Pharmacokinetics-Related Changes for Paracetamol in Older People

### 3.2.1 Characteristics of the Pharmacokinetics Studies

Twenty studies on paracetamol pharmacokinetics were included [24–43]. Eighteen reported on pharmacokinetics parameters, the other two focused mainly on the amount of paracetamol metabolites in older people during prolonged administration [34, 35]. Table 2 provides the characteristics of the included pharmacokinetics studies. The numbers of young and older subjects included in the study ranged from 6 to 28 and 7 to 30, respectively. When all studies were combined, the numbers of young and older subjects were 172 and 314, respectively. Mean or median age and weight of the youth varied from 21 to 30 years and 61 to 81 kg and those of the older people from 66 to 89 years and 52 to 88 kg. Conditions for young and healthy older subjects were ambulatory and active. Frail older people were considered to be dependent of continuous care. The pharmacokinetics parameters derived from literature are provided in Fig. 4 and Table S2A–C (see ESM) for the individual studies as retrieved in the search. Using the ADME sequence, the results of these studies are summarised (see Sects. 3.2.2 to 3.2.4).

### 3.2.2 Influence of Ageing on Paracetamol Absorption

Only three studies compared the oral bioavailability (F) of paracetamol between young and older volunteers based on both oral and intravenous administration in a paired analysis [28, 30, 41] (Table S2). F was similar between young (mean [SD] 98% [0.3]) and older (95% [11]) subjects, as reported by Fulton et al. [41]. Divoll et al., however, reported that older subjects tended to show a reduced F of both tablets (median [range] 72% [57–95]) and elixir (80% [64–94]) compared with younger subjects (79 [59–92] and 87 [70–106], respectively) [29]. However, statistical significance, but not clinical relevance, was attained. In another study from Divoll et al., the influence of age on the potential food–paracetamol interaction was investigated [28]. When paracetamol was administered sober, the F of the elixir (median [range] 80% [64–94]) or tablets (72 [57–95]) tended to be significantly lower in older subjects compared with younger ones (89 [70–106] and 81 [71–92]). When either of them was co-administered with food, there were no differences between the age groups [28].

Three studies investigated the possibility of an association of age with gastric emptying (Table S2, see ESM). They found a similar lag time ( $t_{lag}$ ) and absorption half-life ( $t_{1/2abs}$ ) between younger and older subjects, namely a  $t_{lag}$  (median [interquartile range] of 0.16 h [0.08–0.20] and 0.16 h [0.12–0.22] and a  $t_{1/2abs}$  of 0.11 h [0.06–0.18] and 0.12 h [0.07–0.33], respectively) [26]. Divoll et al. and Rashid and Bateman confirmed these findings [27, 29]. Considering the effect of food, the  $t_{1/2abs}$  was longer in older subjects taking paracetamol elixir ( $p < 0.05$ ), but not when taking tablets ( $p > 0.05$ ), in comparison with younger subjects. The clinical relevance of these results should be interpreted with caution because of the large inter-individual variability irrespective of age [28].

In conclusion, neither rate nor extent of absorption differs clinically significantly between young and robust older subjects. Absorption was not studied in frail older subjects. Therefore, no conclusions can be drawn for this population.

The time at which the maximum concentration is achieved ( $t_{max}$ ) and the maximum concentration ( $C_{max}$ ) are often considered to be absorption-related pharmacokinetics parameters. However, these are secondary parameters and not solely dependent of the absorption phase. To be consistent with literature, the information per individual study on  $t_{max}$  and  $C_{max}$  is reported in Table S2 below the subheading absorption-related parameters (see ESM).

In conclusion,  $t_{max}$  did not change with increased age. For  $C_{max}$  differences between young and robust older subjects are less consistent. However, there tend to be no significant differences between younger and robust older subjects. No information on frail older adults is reported.

### 3.2.3 Influence of Ageing on Paracetamol Distribution

Nine studies reported on the volume of distribution ( $V_d$ ) [24, 25, 29–32, 39–41, 44]. Four studies [37, 38, 42, 43] did not report on  $V_d$ , but the  $V_d$  was calculated based on the reported clearance (CL) and half-life ( $t_{1/2}$ ). The  $V_d$  in younger subjects was between 0.77 and 1.40 L/kg and between 0.74 and 1.08 L/kg in robust older subjects, resulting in a relative lower  $V_d$  of 3.9–22.9% in the older subjects (Table S2 [see ESM], Fig. 4a). However, there is no consistency between the studies on the actual statistical or clinical significance in comparison with younger subjects. The decreased  $V_d$  can physiologically be explained by the age-related greater portion of total body weight consisting of fat, which may be expected to have a larger influence on lipophilic than on hydrophilic drugs. The relative hydrophilic character of paracetamol, together with its incomplete distribution into body fat, could cause  $V_d$  to decrease with age, with a consequent rising of paracetamol plasma concentration in older people.

Age is not the only thing responsible for changes in the  $V_d$  of paracetamol, health condition in the older population can



**Table 2** Patient population and study design characteristics of included studies. Studies are presented in alphabetical order by author

| Study                      | Patient population (male)               | Age (years)   | Weight (kg)   | Conditions  | Route of administration | Dose and other administration specifications   | Sampling [sampling period]                       | Study duration | Analytical method |
|----------------------------|---|---|---|---|-------------------------|--|--|----------------|-------------------|
| Bannwarth et al. [37] 2001 | O: N=12 (8.33)                          | O: 89 (4)<br>[84–95] <sup>a</sup>   | O: 59 (10)<br>[45–74] <sup>a</sup>  | O: Long-term therapy with medication for cardiovascular disorders, mild depression, insomnia<br>Mild–moderate pain for osteoarthritis of hip/knee or for arthritis of shoulder<br>Lab values (blood cell count, aminotransferase, serum albumin, creatinine) were in reference range<br>No smokers, no enzyme-inducing drugs, unstable or active diseases | Enteral (capsule)       | Day 1: 1000 mg q12 h<br>Day 2–6: 1000 mg q8 h<br>Day 7: 1000 mg q24 h<br>With 150 mL water | Blood:<br>Total: 108<br>Per patient: 9 [0–10 h]  | 7 days         | HPLC              |
| Bedjaoui et al. [31] 1984  | N=26<br>Y: N=12 (57.14)<br>O: N=14 (50) | Y: 23.9 (1.1)<br>[21–26] <sup>a</sup><br>O: 81.5 (5.9)<br>[68–90] <sup>a</sup><br>O <sub>M</sub> : 79.71 <sup>c</sup><br>O <sub>F</sub> : 82.67 <sup>c</sup><br>Y <sub>M</sub> : 23.82 <sup>c</sup><br>Y <sub>F</sub> : 26 <sup>c</sup> | Y: 62.3 (6.9)<br>O: 51.8 (12.6)<br>weight specified per sex and age group<br>NR | All: No medication 48 h before paracetamol administration<br>Hepatic and renal lab values within normal range   | Enteral (NR)            | 500 mg<br>Fasted for 8 h before and 4 h after paracetamol administration                   | Blood:<br>Total: 442<br>Per patient: 17 [0–12 h] | 12 h           | HPLC              |

Table 2 (continued)

| Study                                | Patient population (male)                  | Age (years)   | Weight (kg)  | Conditions  | Route of administration            | Dose and other administration specifications  | Sampling [sampling period]                       | Study duration | Analytical method         |
|--------------------------------------|--|---|--|---|------------------------------------|---|--|----------------|---------------------------|
| Briant et al. [32] 1976 <sup>f</sup> | N = 56<br>Y: N = 28 (50)<br>O: N = 28 (50) | Y: 28.15 <sup>c</sup><br>O: 77.95 <sup>c</sup><br>O <sub>M</sub> : 77.4 <sup>c</sup><br>O <sub>F</sub> : 76.5 <sup>c</sup><br>Y <sub>M</sub> : 74.2 <sup>c</sup><br>Y <sub>F</sub> : 28.1 <sup>c</sup>  | Y: 66.4 <sup>c</sup><br>O: 62.65 <sup>c</sup><br>O <sub>M</sub> : 68.8 <sup>c</sup><br>O <sub>F</sub> : 56.5 <sup>c</sup><br>Y <sub>M</sub> : 74.2 <sup>c</sup><br>Y <sub>F</sub> : 58.6 <sup>c</sup>  | Y: No drugs<br>2 weeks before study, except oral contraceptive, no impaired liver function<br>3/28: Elevated blood urea level<br>O: No drugs<br>2 weeks before study.<br>No impaired hepatic function, serum albumin levels, haemoglobin levels<br>17/28: Elevated blood urea level | Enteral (powder)                   | 1000 mg<br>Fasted overnight<br>With little water  | Blood:<br>Total: 280<br>Per patient: 5 [0–6 h]   | 6 h            | Gas-liquid chromatography |
| Divoll et al. [30] 1982 <sup>f</sup> | N = 32<br>Y: N = 16 (50)<br>O: N = 16 (50) | Y: 29.05 [23–37] <sup>b</sup><br>O: 69.7 [61–78] <sup>b</sup><br>Y <sub>M</sub> : 30.8 [24–37] <sup>b</sup><br>Y <sub>F</sub> : 27.3 [23–33] <sup>b</sup><br>O <sub>M</sub> : 70.3 [61–77] <sup>b</sup><br>O <sub>F</sub> : 69.1 [64–78] <sup>b</sup> | Y: 61.2 [47.7–72.7] <sup>b</sup><br>O: 69.6 [45.5–90.9] <sup>b</sup><br>Y <sub>M</sub> : 68.2 [59.1–72.7] <sup>b</sup><br>Y <sub>F</sub> : 54.2 [47.7–65.9] <sup>b</sup><br>O <sub>M</sub> : 79.1 [64.5–90.9] <sup>b</sup><br>O <sub>F</sub> : 60.1 [45.5–81.8] <sup>b</sup> | Y: No diseases, no co-medication<br>O: Ambulatory, active, good general health<br>3/16: Medication for cardiovascular diseases  | IV                                 | 650 mg  | Blood:<br>Total: 480<br>Per patient: 15 [0–12 h] | 12 h           | HPLC                      |
| Divoll et al. [29] 1982              | N = 28<br>Y: N = 16 (50)<br>O: N = 12 (50) | Y: 28.4 [22–39] <sup>b</sup><br>O: 70.7 [61–78] <sup>b</sup>  | Y: 64.5 [47.7–86.4] <sup>b</sup><br>O: 70.4 [45.5–90.9] <sup>b</sup>   | Y: No diseases, no co-medication<br>O: Ambulatory, active, good general health<br>3/16: Medication for cardiovascular diseases  | Enteral (tablet and elixir) and IV | 650 mg<br>1 week elapsing between administration routes<br>Enteral: fasted overnight and 3 h after intake | Blood:<br>Total: 448<br>Per patient: 16 [0–12 h] | 12 h           | HPLC                      |



Table 2 (continued)

| Study                        | Patient population (male)  | Age (years)  | Weight (kg) | Conditions  | Route of administration          | Dose and other administration specifications  | Sampling [sampling period]  | Study duration | Analytical method |
|------------------------------|--|--|-------------|---|----------------------------------|---|---|----------------|-------------------|
| Divoll et al. [28]<br>1982   | N = 24<br>Y: 12 (50)<br>O: 12 (50)                                       | NR   | NR          | Y: Free of any identifiable medical disease<br>O: Ambulatory, active, good, general health<br>3/12: Use of cardiovascular drugs | Enteral (elixir or tablet) or IV | 650 mg Administered on 5 occasions separated by 1 week<br>1. IV<br>2. Tablets with 100–200 mL water<br>3. Elixir with 19.5 mL water<br>4. Tablets 30 min after standardised breakfast<br>5. Elixir 30 min after standardised breakfast<br>2+3: Fasted overnight and fasted 3 h after intake<br>4+5: Fasted 3 h after intake | Blood:<br>Total: 384<br>Per patient: 16 [0–12 h]                      | 12 h           | HPLC              |
| ElIsmers et al. [42]<br>1990 | N = 55<br>O <sub>fit</sub> : 29 (37.9)<br>O <sub>frail</sub> : 26 (42.3) | O <sub>fit</sub> : 77.3 (8.2) [64–94] <sup>a</sup><br>O <sub>frail</sub> : 83.5 (7.3) [64–97] <sup>a</sup> | NR          | O <sub>fit</sub> : Living independently<br>O <sub>frail</sub> : Not living independently, mobility score from 1 to 5            | Enteral (tablet)                 | 1000 mg   | Blood:<br>Total: 330<br>Per patient: 6 [0–24 h]<br>Urine:<br>[0–24 h] | 24 h           | HPLC              |

Table 2 (continued)

| Study                         | Patient population (male)                  | Age (years)  | Weight (kg) | Conditions   | Route of administration | Dose and other administration specifications           | Sampling [sampling period]                      | Study duration | Analytical method      |
|-------------------------------|--|--|-------------|--|-------------------------|--|---|----------------|------------------------|
| Fulton et al. [41] 1979       | N = 23<br>Y: N = 11 (NR)<br>O: N = 12 (NR) | Y: 23.9 (1.2) <sup>d</sup><br>O: 75.8 (1.6) <sup>d</sup>     | NR          | All: No drugs inducing hepatic microsomal oxidation<br>Normal values of serum bilirubin, aspartate transaminase, alkaline phosphatase, albumin and renal function (sodium, potassium, bicarbonate, urea, creatinine) | Enteral (tablet) and IV | 500 mg<br>Separated occasions 1 wk apart               | NR  | 6 h            | Gas chromatography     |
| Gainsborough et al. [26] 1993 | N = 38<br>Y: 19 (NR)<br>O: 19 (NR)         | Y: 24.8 [20–33] <sup>b</sup><br>O: 75.0 [69–86] <sup>b</sup> | NR          | All: No gastric, oesophageal, liver or other diseases<br>No drugs, alcohol, cigarettes 24 h before paracetamol intake  | Enteral (tablet)        | 20 mg/kg with 250 mL water<br>Fasted 9 h before intake | Blood:<br>Total: 570<br>Per patient: 15 [0–3 h] | 3 h            | Enzyme-specific method |

Table 2 (continued)

| Study                      | Patient population (male)                                       | Age (years)  | Weight (kg)   | Conditions   | Route of administration | Dose and other administration specifications          | Sampling [sampling period]   | Study duration | Analytical method |
|----------------------------|---|--|---|--|-------------------------|---|--|----------------|-------------------|
| Hagen et al. [36]<br>1991  | N=22<br>Y: 6 (50)<br>O: 16 (18.75)                              | Y: 30 [NR] <sup>b</sup><br>O: 81 [70–90] <sup>b</sup>          | Y: 67 [55–80] <sup>b</sup><br>O: 54 [35–72] <sup>b</sup>        | <b>All:</b> No ongoing paracetamol treatment, dementia/confusion, malabsorption disorders, inflammatory or malignant intestinal disease, decompensated heart failure, liver disease, kidney insufficiency or hyper- or hypofunctioning of thyroid<br><b>Y:</b> Healthy<br><b>O:</b> Stable clinical condition, aged > 70 years<br>9/16: Faeces in rectum | Enteral (suppository)   | 500 mg<br>Fasted overnight and for 2.5 h after intake | <i>Blood:</i><br>Total: 154<br>Per patient: 7<br>[0–8 h]   | 8 h            | NR                |
| Kamali et al. [43]<br>1993 | N=19<br>O <sub>H</sub> : 9 (78)<br>O <sub>NIDDM</sub> : 10 (90) | O <sub>H</sub> : 69.3 (2.3)<br>O <sub>NIDDM</sub> : 67.1 (3.0) | O <sub>H</sub> : 70.5 (10.9)<br>O <sub>NIDDM</sub> : 77.0 (9.6) | <b>All:</b> Normal renal and hepatic function, no smokers<br><b>O<sub>NIDDM</sub>:</b> Received combination of hypoglycaemic agents and restricted carbohydrate intake.<br>7/10 patients received other cardiovascular drugs (not taken during the study period)   | IV                      | 500 mg  | <i>Blood:</i><br>Total: 228<br>Per patient: 12<br>[0–6 h]<br><i>Urine:</i><br>Before study<br>[0–24 h] | 24 h           | HPLC              |

Table 2 (continued)

| Study                      | Patient population (male)  | Age (years)  | Weight (kg)  | Conditions   | Route of administration | Dose and other administration specifications     | Sampling [sampling period]  | Study duration | Analytical method |
|----------------------------|--|--|--|--|-------------------------|--|---|----------------|-------------------|
| Liukas et al. [39]<br>2011 | N=40<br>Y <sub>20-40y</sub> : N=10 (70)<br>O <sub>60-70y</sub> : N=10 (50)<br>O <sub>70-80y</sub> : N=10 (60)<br>O <sub>80-90y</sub> : N=10 (10) | Y <sub>20-40y</sub> : 27 (5)<br>O <sub>60-70y</sub> : 66 (3)<br>O <sub>70-80y</sub> : 77 (3)<br>O <sub>80-90y</sub> : 84 (3) | Y <sub>20-40y</sub> : 81 (14)<br>O <sub>60-70y</sub> : 83 (9)<br>O <sub>70-80y</sub> : 82 (13)<br>O <sub>80-90y</sub> : 68 (8) | <b>All:</b> No hepatic, renal, neurological, endocrine, haematological, metabolic or gastrointestinal diseases, BMI > 35 kg/m <sup>2</sup> , strong inhibitors or inducers of cytochrome P450 enzymes<br><b>Y:</b> Arthroscopic anterior cruciate ligament operation of knee<br><b>O:</b> Elective knee prosthesis operation | IV                      | 1000 mg  | <i>Blood:</i><br>Total: 880<br>Per patient: 22 [0–24 h]                             | 24 h           | HPLC              |
| Miners et al. [38]<br>1988 | N=16<br>Y: N=8 (100)<br>O: N=8 (100)   | Y: 20.8 (2.4) [18–26] <sup>a</sup><br>O: 79.3 (7.2) [72–92] <sup>a</sup>   | Y: 74.9 (5.3) [69–82] <sup>a</sup><br>O: 77.2 (3.0) [72–87] <sup>a</sup>   | <b>Y:</b> Healthy, no medication<br>1 week before study, non-smokers<br><b>O:</b> Ambulatory, no drug influencing paracetamol metabolism or extensively conjugated, non-smokers, no respiratory, unstable cardiac, renal, hepatic diseases<br>Liver and renal lab values within reference range                              | Enteral (tablet)        | 1000 mg<br>Fasted overnight and 3 h after intake | <i>Blood:</i><br>Total: 160<br>Per patient: 10 [0–8 h]<br><i>Urine:</i><br>[0–12 h] | 12 h           | HPLC              |

Table 2 (continued)

| Study                          | Patient population (male)            | Age (years)   | Weight (kg)  | Conditions  | Route of administration | Dose and other administration specifications   | Sampling [sampling period]   | Study duration | Analytical method |
|--------------------------------|--------------------------------------|---|--|---|-------------------------|--|--|----------------|-------------------|
| Moreau et al. [40] 1993        | <b>O:</b> N = 12 (75)                | <b>O:</b> 77 (7)<br><b>O<sub>M</sub>:</b> 77.78 (NR)<br><b>O<sub>F</sub>:</b> 75 (NR) | <b>O:</b> 66 (15)<br><b>O<sub>M</sub>:</b> 70.55 (NR)<br><b>O<sub>F</sub>:</b> 53 (NR) | <b>O:</b> Operation due to arthritis of the lower limbs (continuous spinal anaesthesia)<br>Exclusion: No paracetamol 48 h before study<br>Insufficient liver or renal function, paracetamol allergy<br><b>All:</b> Aortic surgery patients<br>No clearance rate < 30 mL/min | IV                      | 2000 mg propacetamol chloral hydrate (= 1000 mg paracetamol)   | <i>Blood and CSF:</i><br>Total: 168<br>Per patient: 14 [0.25–6 h]  | 6 h            | HPLC              |
| Pickering et al. [35] 2011     | N = 30*                              | 65 (11)   | 77 (14)  |   | IV                      | 1000 mg q6 h   | <i>Blood:</i><br>Total: 60<br>Per patient: 2 [days 0 and 4]<br><i>Urine:</i><br>[0–24 h] on days 0 and 4 | 4 days         | HPLC              |
| Pujos-Guillot et al. [34] 2012 | <b>O:</b> N = 10                     | 74.0 (1.2) <sup>d</sup>   | 74.2 (3.6) <sup>d</sup>  | <b>O:</b> Arthritic pain<br>No treatment with N-acetylcysteine  | NR                      | 3000 mg/day  | <i>Blood:</i><br>Total: 20<br>Per patient: 2 [days 0 and 14]<br><i>Urine:</i><br>[0–24 h] days 0 and 14  | 14 days        | HPLC              |
| Rashid and Bateman [27] 1990** | N = 14<br><b>O:</b> 7<br><b>Y:</b> 7 | <b>O:</b> 70 (1.6) <sup>e</sup><br><b>Y:</b> 23 (1.3) <sup>e</sup>                    | NR   | No history of gastrointestinal or renal disease, no concurrent medication, no paracetamol in wash-out weeks, no alcohol, drugs or smoking for 48 h before study<br>Normal physical examination and ECG  | Enteral (solution)      | 1000 mg 10 min after intake placebo or atropine<br>Fasted overnight and 2 h after paracetamol intake | <i>Blood:</i><br>Total: 168<br>Per patient: 12 [0–6 h]   | 6 h            | HPLC              |

Table 2 (continued)

| Study                         | Patient population (male)                  | Age (years)  | Weight (kg)  | Conditions  | Route of administration | Dose and other administration specifications                                      | Sampling [sampling period]                                 | Study duration | Analytical method |
|-------------------------------|--|--|--|---|-------------------------|---|--|----------------|-------------------|
| Robertson et al. [33] 1992*** | O: N = 8                                   | O: 73 [65–78] <sup>b</sup>                                 | O: 78.8 [71–90] <sup>b</sup>                                   | O: Healthy, no history of gastrointestinal disease. One subject received medication (digoxin, warfarin). These were not taken on the morning of the study. One subject smoked (no smoking 2 weeks before study)     | Enteral (solution)      | 1500 mg with 100 mL water<br>Overnight fast and semi-recumbent for 4 h after dose | Blood:<br>Total: 144<br>Per patient: 18                    | 4 h            | NR                |
| Triggs et al. [25] 1974       | N = 13<br>Y: N = 6 (100)<br>O: N = 7 (100) | Y: 24 [22–30] <sup>b</sup><br>O: 80.9 [73–91] <sup>b</sup> | Y: 75.17 [60–95] <sup>b</sup><br>O: 57.14 [51–68] <sup>b</sup> | All: Serum urea, creatinine, bilirubin, alkaline phosphatase, GOT, GPT, plasma protein in normal range<br>Y: No medication 48 h before paracetamol administration<br>O: 3/7 other medication (digoxin, methyl(dopa) | Enteral (oral solution) | 14.3 mg/kg<br>2 h after breakfast   | Blood:<br>Total: 132<br>Per patient: 8 (Y), 12 (E) [0–7 h] | 24 h           | NR                |


Data are presented as median [range] or mean (SD) unless otherwise specified. <sup>a</sup>mean (SD) [range], <sup>b</sup>mean [range], <sup>c</sup>mean, <sup>d</sup>mean (SEM)

CSF cerebrospinal fluid, ECG electrocardiogram, GOT glutamate oxaloacetate transaminase, GPT glutamic pyruvic transaminase, HPLC high-performance liquid chromatography, IV intravenous, NR not reported, O older people, O<sub>F</sub> older female, O<sub>H</sub> healthy older people, O<sub>M</sub> older male, O<sub>NIDDM</sub> older patient with non-insulin-dependent diabetic mellitus, q (quaque) every, SEM standard error of the mean, Y young subject, Y<sub>F</sub> young female, Y<sub>M</sub> young male, y years

\*As influence of age was a secondary aim of this study, the study did not specify the number of subjects in young and older subgroups for number of patients, weight and age

\*\*/\*\*\*This paper compared paracetamol vs paracetamol + atropine (\*\*\*) or paracetamol vs paracetamol + levodopa (\*\*\*), where paracetamol served as a marker for gastric emptying. Only the paracetamol pharmacokinetic values without influence of atropine/levodopa are presented

†Characteristics of patients in this study were specified separately for men and women and are expressed as the mean of these two groups together in this table



**Fig. 4** **a** Volume of distribution (L/kg), **b** clearance (L/kg/h) values of paracetamol and **c** formation clearance (L/kg/h) values from paracetamol to its metabolites (in young and older subjects derived from literature). Notes: For Liukas et al. [39], the clearance values of the older subgroups used in their original study (60–70, 70–80, 80–90 years)

were pooled to obtain one ‘older people’ clearance value. For Bannwarth et al. [37], Kamali et al. [43] and Miners et al. [38], the volume of distribution was not reported but calculated based on the reported clearance and half-life by study



also affect pharmacokinetics. Wynne et al. studied the association of age and frailty on the  $V_d$  (L/kg) of paracetamol. They reported the lowest  $V_d$  in frail older people, namely 16.9 and 20.3% lower (not statistically significant) in comparison with robust older and young subjects, respectively [24]. Ellmers et al. support this finding, be it with only a decrease (4.7%) in frail compared with robust older people [42], possibly due to small subgroups and a large degree of variability within the subgroups. Comparing robust older subjects with those with diabetes mellitus, only a small decrease (7%) in  $V_d$  was noted in older subjects with diabetes [43].

Five studies [30–32, 40] investigated sex-related differences in pharmacokinetic parameters between robust male and female older adults, of which four studies reported a smaller  $V_d$  in women compared with men ( $p < 0.05$ ), ranging from 8.5 to 17.5% [30–32]. This is probably caused by the larger proportion of fat in a woman's total body weight.

It is reasonable to state that  $V_d$  decreases with increasing age, most pronouncedly in frail older people. Changes in  $V_d$  determine the influence of the loading dose, and the elimination half-life. Both statistical and clinical significance are still unknown.

### 3.2.4 Influence of Ageing on Paracetamol Metabolism and Elimination

Eleven out of 13 studies reported reduced paracetamol CL (29–45.7%), varying from 0.20 to 0.38 L/h/kg in robust older subjects and 0.28 to 0.7 L/h/kg in younger subjects (Fig. 4b, Table S2 [see ESM]), while Miners et al. [38] and Triggs et al. [25] reported no significant differences. Another study, comparing paracetamol CL on days 1 and 7 during repeated administration, reported no paracetamol accumulation. However, this does not imply anything regarding possible accumulation of the (toxic) metabolites.

Additional factors besides age, such as disease, concomitant medication or general physical status (e.g. frailty), may influence paracetamol metabolism. Ellmers et al. reported a significant decrease (26.4%) in paracetamol CL in frail compared with robust older subjects [42], which was supported by Wynne et al. when paracetamol CL was expressed in terms of body weight [24]. Paracetamol CL was 46.8% lower in frail older subjects compared with young subjects ( $p < 0.01$ ) and 32.4% lower compared with robust older subjects ( $p < 0.01$ ). When CL was expressed per unit volume of liver, no significant differences were found between young and robust older subjects, but it was significantly reduced in the frail subjects: 37.5 and 32.9% lower when compared with young and robust older cases, respectively. This indicates that frailty and/or disease state also decreases CL. No difference (4%) in paracetamol CL was reported between older subjects with and without diabetes [43].

A few pharmacokinetics studies focused on the contribution of the different metabolic routes (Fig. 4c), with conflicting results. Miners et al. reported no significant change in the formation fraction to glucuronide and to oxidative metabolites [38]. However, formation fraction to sulphate and the excretion of unchanged paracetamol was 18.2 and 30.0% lower in older subjects compared with their younger counterparts [38]. Pickering et al. reported a significant decrease in the amount of sulphate excreted in urine in participants aged  $\geq 65$  years but not in those  $< 65$  years, with a decrease in glutathione reserves and some more oxidative metabolites ( $p > 0.05$ ) [35]. Next to a significant 36.4% decrease in fraction of sulphate (in robust older vs young subjects), another study reported also a significant 13.3% decrease in formation fraction of glucuronide (in robust older vs young subjects), but reported no differences in excretion of unchanged paracetamol between young and robust older subjects [24]. The oxidative metabolites were not measured. However, when calculating the fraction based on the fact that this is the remaining unexplained part of the total paracetamol CL, there seems to be no difference between young and robust older subjects. For frail older subjects, the formation fractions of glucuronide and sulphate were decreased compared with the young (60 and 40%, respectively) and robust older subjects (53.9 and 5.7%, respectively) [24]. For older people with diabetes, a significant decrease in formation fraction to sulphate (33.3%) and a significant increase in renal excretion of unchanged paracetamol (50%) compared with robust older subjects were reported. The formation fraction of glucuronide remained unchanged.

In conclusion, paracetamol CL decreases not only with age but even more with frailty and/or disease state. Conflicting and limited results about the fractions of paracetamol into the different metabolic pathways still exist.

A secondary pharmacokinetics parameter,  $t_{1/2}$ , is directly related to  $V_d$  and inversely to CL. This parameter will not be discussed in the text but is reported in Table S2 (see ESM) for the individual studies.

### 3.3 Safety-Related Changes for Paracetamol in Older People

Seven studies reported on adverse events (hepatotoxicity, nephrotoxicity and gastrointestinal toxicity) [45–51], possibly related to paracetamol use in older subjects. The studies are presented in detail in Table 3 while patterns of safety-related changes in older people are summarised below.

Paracetamol hepatotoxicity has been investigated in multiple studies, but with only a few studies focusing on age. Mitchell et al. reported that alanine aminotransferase (ALAT) concentrations in the frail older and robust older subjects were within and slightly above the reference range, respectively, while the highest serum ALAT

**Table 3** Observations on the safety of paracetamol at therapeutic dosages

| Adverse event  | Study                | Study design   | Population   | Determinant  | Paracetamol use  | Conclusions   |
|----------------|----------------------|--|--|--|--|---|
| Hepatotoxicity | Mitchell et al. [45] | Observational cohort study                                       | <i>Young</i><br>Paracetamol group: N = 11<br>[mean age (SD): 35.6<br>(11.9)]<br>Control group: N = 8 [46.3<br>(13.2)]  | ALAT at baseline, on<br>day 5<br>Paracetamol concentration<br>on day 5 | Oral paracetamol group:<br>3000–4000 mg per day<br>Control group: NR | ALAT in older robust and<br>frail subjects within and<br>slightly above reference<br>range<br>Highest serum ALAT in<br>young subjects<br>Older frail subjects receiv-<br>ing lowest paracetamol<br>dosage had highest<br>paracetamol concentration<br>on day 5  |
|                |                      |  | <i>Fit older</i><br>Paracetamol group: N = 12<br>[81.7 (5.4)]<br>Control group: N = 12<br>[81.0 (5.5)]<br><i>Frail older</i><br>Paracetamol group: N = 13<br>[85.4 (6.2)]<br>Control group: N = 15<br>[83.1 (4.7)] |  |  |   |
| Hepatotoxicity | Jahr et al. [46]     | Pooled analysis of 3<br>randomised placebo-<br>controlled trials | <i>Young</i> (< 65 y)<br>Paracetamol group: N = 56<br>[50.45 years]<br>Control group: N = 68<br>[31.5]<br><i>Older</i><br>Paracetamol group: N = 48<br>[73.8]<br>Control group: N = 49<br>[71.9]                   |  | Intravenous paracetamol<br>group: 1000 mg<br>Control group: NR       | <b>Study 1<sup>a</sup></b><br>Normal: $p = 0.481$<br>> 1 ULN to < 3 ULN:<br>$p = 0.585$<br><b>Study 2</b><br>Normal: $p = 0.438$<br>> 1 ULN to < 3 ULN:<br>$p = 0.634$<br><b>Study 3</b><br>Normal: $p = 0.449$<br>> 1 ULN to < 3 ULN:<br>$p = 1.000$<br>$\geq 3$ ULN: $p = 1.000$<br>No significant difference<br>between paracetamol and<br>placebo groups in older<br>subjects concerning liver<br>function values<br>Overall incidence of adverse<br>events was comparable<br>between paracetamol<br>and placebo groups and<br>between age groups |

Table 3 (continued)

| Adverse event             | Study                 | Study design                                | Population   | Determinant  | Paracetamol use   | Conclusions  |
|---------------------------|-----------------------|---|--|--|---|--|
| Nephrotoxicity            | Koppert et al. [48]   | Randomised placebo-controlled study         | <i>Older</i> : $N=75$<br>(mean [range] 76.5 y [65–94]; 70.9 kg [47–127])   | Markers of renal function (serum Cystatin C, creatinine, blood urea nitrogen, creatinine clearance, urinary sodium, potassium, albumin, alpha-1-microglobulin) | Intravenous paracetamol: 1000 mg<br>Parecoxib: 40 mg<br>Saline: NR            | Decrease in creatinine clearance in the paracetamol group ( $-17.1$ mL/min) and placebo group ( $-23.4$ mL/min) ( $p > 0.05$ )<br>First 2 h after initial dose of parecoxib, creatinine clearance decreased ( $-49.2$ mL/min) ( $p < 0.05$ )<br>All treatment groups:<br>urine albumin, alpha-1-microglobulin, sodium and potassium were slightly increased ( $p > 0.05$ )<br>No differences in paracetamol use between inpatients and control with gastrointestinal bleeding<br>Paracetamol use was not associated with either gastric or duodenal ulcer bleeding |
| Gastrointestinal toxicity | Alexander et al. [47] | Hospital prescribing case-control study     | <i>Older</i><br>In-patients: $N=1878$<br>Control: NR   | Diagnosis of gastrointestinal bleeding and paracetamol use   | Any paracetamol dose  | No differences in paracetamol use between inpatients and control with gastrointestinal bleeding  |
| Gastrointestinal toxicity | Langman et al. [49]   | Case-control study                          | <i>Older</i><br>Patients: $N=1121$<br>Control: $N=2115$  | Diagnosis of gastrointestinal bleeding and paracetamol use   | Any paracetamol dose  | Paracetamol use was not associated with either gastric or duodenal ulcer bleeding  |
| Gastrointestinal toxicity | Rahme et al. [51]     | Population-based retrospective cohort study | <i>Older</i><br>$N=21,207$ (with paracetamol prescription)<br>(26,978 with NSAID prescription)   | High or low paracetamol (or NSAID) prescription and rates of gastrointestinal events   | High-dose paracetamol: 2601–3250 mg/day<br>Low-dose paracetamol: <2600 mg/day | RR high-dose paracetamol: 1.27 [95% CI 1.13–14.3]<br>RR low-dose paracetamol: 1.34 [95% CI 1.15–1.54]<br>RR high-dose NSAID: 0.98 [95% CI 0.85–1.13]   |
| Gastrointestinal toxicity | Rahme et al. [52]     | Population-based retrospective cohort study | <i>Older</i><br>$N=644,183$<br>High-dose paracetamol: 1,597,725 (31.6% with PPI prescriptions)<br>Low-dose paracetamol: 3,641,140 (28.3% with PPI prescriptions) | High- or low-dose paracetamol with or without PPI (combination of NSAID and paracetamol with or without PPI or NSAID with or without PPI)                      | High-dose paracetamol: > 3 g/day<br>Low-dose paracetamol: $\leq 3$ g          | In comparison with low-dose paracetamol without PPI:<br>HR high-dose paracetamol without PPI: 1.2 [1.03–1.40]<br>HR high-dose paracetamol with PPI: 0.95 [0.81–1.11]<br>HR NSAID and paracetamol without PPI: 2.15 [1.35–3.40]<br>HR NSAID and paracetamol with PPI: 2.55 [1.98–3.28]  |

ALAT alanine amino-transferase, CI confidence interval, HR hazard ratio,  $N$  number of patients, NR not reported, NSAID non-steroidal anti-inflammatory drugs, PPI proton pump inhibitor, RR relative risk, ULN upper limit of normal

<sup>a</sup>Values only reported for older subjects

concentrations were observed in the younger subjects [45]. Although frail older adults received the lowest dosages of paracetamol, paracetamol concentrations were highest in this group [45] (Table 3). In patients > 65 years of age, Jahr et al. found no significant differences in liver enzyme values between the paracetamol and placebo groups (Table 3) [46]. The overall incidence of adverse events was comparable between the paracetamol and placebo groups and between the young and older subjects. A detailed overview of all the adverse events specified in the three individual studies can be found in the paper of Jahr et al. [46].

One study investigated the effect of paracetamol, parecoxib and placebo on the renal function in older people [48] (Table 3). No significant decrease in creatinine CL was observed in both the paracetamol group and placebo group. For all treatment groups, urine albumin,  $\alpha$ -1-microglobulin, sodium and potassium were slightly, but not significantly, increased.

Four retrospective studies [47, 49, 51, 52] explored the association between paracetamol use and gastrointestinal toxicity, of which two studies reported no significant differences in paracetamol use between hospitalised patients and controls with gastrointestinal bleeding [47, 49] or duodenal ulcer bleeding [49]. Rahme et al. concluded that (after adjustment for 'risk susceptibility'—likelihood of receiving paracetamol e.g. older, sicker, with prior gastrointestinal events) patients who took higher-dose paracetamol (2601–3250 or > 3250 mg/day) were more likely to experience a gastrointestinal event compared with those who took low-dose paracetamol ( $\leq$  2600 mg/day) [51]. These higher-dose paracetamol users experienced similar rates of gastrointestinal events as patients who took a high-dose non-steroidal anti-inflammatory drug (NSAID) [51]. Another study by Rahme et al. reported an increased (non-significant) risk of gastrointestinal events in the high-versus low-dose paracetamol group without a proton pump inhibitor (PPI); this risk was slightly less when the low-dose group used a PPI. The highest risk was in the combination group of NSAID and paracetamol with or without a PPI (Table 3) [52].

In conclusion, a very limited number of studies concluded that paracetamol administration at therapeutic doses (3000–4000 mg/day) did not result in elevated liver enzymes in older people and that glomerular and tubular functions were transiently affected in all older people after orthopaedic surgery. However, the effects were limited and not significant. The evidence concerning the increased risk of gastrointestinal events after paracetamol usage remains inconsistent and therefore not convincing. Overall, due to limited and heterogeneous evidence, it was difficult to draw firm and meaningful conclusions on changed risk in paracetamol safety in older people.

## 4 Discussion

In this review, we applied the paediatric study decision tree [21, 22] extrapolated to robust and frail older people for paracetamol. Based on this study decision tree concept, we performed a search on what is already known on pharmacokinetics and safety to delineate the knowledge gaps. Our ultimate goal is to describe a roadmap to reach evidence-based dosing advice for this heterogeneous and increasing population. Concerning the pharmacokinetics studies of paracetamol in older subjects, many ( $n=20$ ) non-compartmental pharmacokinetics analyses were performed (Table 2 and Table S1 [see ESM]), most of which compared paracetamol pharmacokinetics between young and (robust) older subjects. The limited number of studies ( $n=3$ ) included in this review revealed no changes in absorption with ageing [28, 29, 41]. In contrast, the  $V_d$  was decreased in older subjects and even further decreased in frail older subjects compared with younger subjects. (Table S2 [see ESM], Fig. 4a). Similar to  $V_d$ , age and frailty are associated with reduced paracetamol CL (Table S2 [see ESM], Fig. 4b). This review reveals that pharmacokinetics-related knowledge gaps still remain, and these will be discussed below. Thereafter, we will focus on what is already known on safety and subsequently highlight the safety-related knowledge gaps.

Although this review showed cumulative evidence around the impact of age and frailty on pharmacokinetics parameters, re-illustration of the importance of other factors in this special population of older adults, such as drug- and patient-specific factors (e.g. potential covariates) that could influence paracetamol pharmacokinetics are underreported or unknown. For drug-specific factors, limited research, especially on absorption, has been conducted on paracetamol when rectally administered in robust and frail older subjects. In addition, new routes of administration (buccal) are investigated, which should also be investigated in relation to the pharmacokinetics of oral and/or intravenous routes [53, 54]. Concerning the patient-specific factors, the older patient population is very heterogeneous (e.g. robust, frail, polypharmacy comorbidities). When focusing on robust older subjects, the focus of the performed pharmacokinetics studies is mainly on the question of whether a significant difference in pharmacokinetics parameters exists between the above-mentioned group and young subjects. This is certainly important when performing a first pharmacokinetics study. However, this review revealed differences in pharmacokinetics parameters such as  $V_d$  and CL between young and older robust subjects. Consequently, the question should no longer be if the difference is statistically significant, but whether the difference in CL and/or  $V_d$  in robust older

subjects is clinically relevant enough for dose adaptation in older people.

Population pharmacokinetics modelling can be a useful tool, not only to predict pharmacokinetics parameters, but also to develop more evidence-based dosing in special populations [55]. Patient-related (i.e. age, frailty, multi-morbidity, polypharmacy) and treatment characteristics (i.e. route of administration) can thereby be used to (partly) understand and explain the inter-individual and intra-individual variability in these pharmacokinetics parameters in older subjects. Therefore, those covariates can be used to determine if and how dosing can be individualised. After the development of such a pharmacokinetics model, the dosage needed to reach a specific target concentration can be developed. The target concentration ( $C_{ss\text{mean}}$ ) to reach analgesia is 10 mg/L [56]. This specific value as a target concentration in older subjects is not specifically investigated, but can be assumed to be similar. After the development of a pharmacokinetics model and model-based dosing, it would be of the utmost importance to prospectively validate the model-based dosing in a clinical study, not only to investigate whether the target concentration is reached, but also to investigate if the safety values are within the reference range. A first step could be to evaluate the already performed pharmacokinetics studies on quality and the amount of data, such as clinical characteristics, drug concentrations in plasma, number of patients and time of sampling, retrieved from these studies in order to perform a pooled-pharmacokinetics analysis [55]. Such a pooled analysis has already been performed by Allegaert et al. [57] with the aim to study all common covariates in adults in datasets on intravenous paracetamol. In this way, a pooled analysis could be performed with all pharmacokinetics data of the older population. After developing a pharmacokinetics model specific for older people, a next step could be to design a new study with specific focus on, for example, additional covariates that have not yet been studied in already published datasets and that could possibly explain the residual variability. In this way, we should use these already available datasets and published Pop pharmacokinetics models to put new datasets into these perspectives. This is a very effective approach to explore additional covariates or specific subpopulations, but should be preceded by a critical assessment of the published models [39, 58].

After this information has been collected for the more homogenous population within the older population, studies can be extended to investigate the influence of frailty on the pharmacokinetics of paracetamol. Until now, only two studies have investigated the difference in paracetamol pharmacokinetics in robust versus frail subjects; clear differences were found between these two older populations [24, 42]. However, a major limitation of these studies is the small number of study participants. Besides, the definition of frailty has since changed, as described in the recent

EMA reflection paper on physical frailty [59]. Ellmers et al. defined frailty as immobility (scale 1–5) and living dependently, while Wynne et al. defined frail patients as continuously needing hospital care due to chronic disabling conditions (cerebrovascular or musculoskeletal disease). Despite the limited definitions of frailty, differences in pharmacokinetics parameters between fit and frail existed. Likewise, it has not been investigated if and how dosages should be adapted based on the pharmacokinetics in frail older subjects. Lastly, the influence of common multi-morbidity and polypharmacy in older people on the pharmacokinetics of paracetamol has not yet been investigated.

Another knowledge gap that needs to be further explored is the extent of accumulation of paracetamol and its metabolites, especially the active toxic metabolite of paracetamol, NAPQI (Fig. 1). Bannwarth et al. found no accumulation of paracetamol after 7 days of therapeutic paracetamol dosing [37]. However, future studies should not only focus on paracetamol, but also on the toxic metabolite. Data on the fraction of formation of paracetamol into its metabolites are still limited and conflicting (Fig. 4c) and should therefore be investigated. Based on the limited studies focusing on the formation CL of the different metabolites, it seems that age-related changes mostly relate to reduced conjugation capacity, rather than to the formation of the oxidative metabolite. This review shows that most studies used high-performance liquid chromatography analysis to measure paracetamol as well as its metabolites. By using this method it is difficult to quantify oxidative metabolites due to assay sensitivity issues [13]. As ultra-performance liquid chromatography–mass spectrometry techniques are available (and validated) to measure paracetamol and all metabolites, these can be used in future studies [13].

Compared with the large number of pharmacokinetics studies performed, very few studies addressed the safety of paracetamol when administered at regular doses. One of the main concerns, in any population, is the risk of hepatotoxicity [17]. A source of information concerning age-related changes to toxicological mechanisms in paracetamol is reported by Mitchell et al. [60]. Raised values of liver enzymes have been reported even when paracetamol was administered at normal dosages in healthy adults [61]. Based on the—albeit limited—observations retrieved in our search, there is no evidence that supports a higher incidence of hepatotoxicity in normal paracetamol dosages in older subjects [45, 46]. This is in line with the fact that age-related changes in paracetamol formation CL mostly occur in impaired conjugation rather than in the formation of oxidative metabolites [24, 35, 38]. Overall, due to limited and heterogeneous evidence, it was difficult to draw firm and meaningful conclusions on changed risk in paracetamol safety in older people. Safety of paracetamol (i.e. hepatic, gastrointestinal) should be investigated more profoundly,



preferably simultaneously with pharmacokinetics, in clinical trials but also in the clinical setting.

## 5 Conclusion

Differences in paracetamol CL and  $V_d$  between young and robust older people have been reported, with an even further decrease in those pharmacokinetics parameters in frail older people. Based on the—albeit limited—observations retrieved in our search, there is no evidence that supports a higher incidence of hepatotoxicity in paracetamol at normal dosages in older subjects. Overall, due to limited and heterogeneous evidence, it was difficult to draw firm and meaningful conclusions on changed risk for paracetamol safety in older people. Population pharmacokinetics modelling can be considered a valuable tool to develop more evidence-based dosing advice for older people. In addition, more clinical studies with enriched clinical characteristics (e.g. comorbidity, comedication, frailty) should be conducted to study both the pharmacokinetics of paracetamol (and its metabolites) and its safety parameters.

**Acknowledgements** We thank Wichor Bramer, from the Medical Library Erasmus Medical Centre, for helping to develop and perform the systematic search strategy. We thank Ko Hagoort for linguistic editing of the manuscript.

## Compliance with Ethical Standards

**Conflict of interest** Paola Mian, Karel Allegaert, Isabel Spriet, Dick Tibboel and Mirko Petrovic declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

**Funding** Isabel Spriet is partially funded by the Clinical Research Fund of the University Hospitals Leuven, Belgium.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

## References

- Nations, U. World Population Ageing Report. 2015 2015 [cited 2017 11/15].
- Klotz U. Pharmacokinetics and drug metabolism in the elderly. *Drug Metab Rev.* 2009;41(2):67–76.
- Shah SM, et al. Quality of prescribing in care homes and the community in England and Wales. *Br J Gen Pract.* 2012;62(598):e329–36.
- Ferreira ML, McLachlan A. The challenges of treating sciatica pain in older adults review. *Drugs Aging.* 2016;33(11):779–85.
- Haasum Y, et al. Pain treatment in elderly persons with and without dementia: A population-based study of institutionalized and home-dwelling elderly. *Drugs Aging.* 2011;28(4):283–93.
- Hartikainen SA, et al. Balancing pain and analgesic treatment in the home-dwelling elderly. *Ann Pharmacother.* 2005;39(1):11–6.
- Aubrun F, Marmion F. The elderly patient and postoperative pain treatment. *Best Pract Res Clin Anaesthesiol.* 2007;21(1):109–27.
- Cherubino P, et al. The management of chronic pain in important patient subgroups. *Clin Drug Investig.* 2012;32(Suppl 1):35–44.
- Fitzcharles MA, Lussier D, Shir Y. Management of chronic arthritis pain in the elderly. *Drugs Aging.* 2010;27(6):471–90.
- Reid MC, Shengelia R, Parker SJ. Pharmacologic management of osteoarthritis-related pain in older adults. *Am J Nurs.* 2012;112(3 Suppl 1):S38–43.
- Cao X, et al. An update on pain management for elderly patients undergoing ambulatory surgery. *Curr Opin Anaesthesiol.* 2016;29(6):674–82.
- Marcum ZA, Duncan NA, Makris UE. Pharmacotherapies in Geriatric Chronic Pain Management. *Clin Geriatr Med.* 2016;32(4):705–24.
- Flint RB, et al. Quantification of acetaminophen and its metabolites in plasma using UPLC-MS: doors open to therapeutic drug monitoring in special patient populations. *Ther Drug Monit.* 2017;39(2):164–71.
- Prescott LF. Kinetics and metabolism of paracetamol and phenacetin. *Br J Clin Pharmacol.* 1980;10:291S–8S.
- Clements JA, Critchley JA, Prescott LF. The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. *Br J Clin Pharmacol.* 1984;18(4):481–5.
- Critchley JA, et al. Inter-subject and ethnic differences in paracetamol metabolism. *Br J Clin Pharmacol.* 1986;22(6):649–57.
- Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. *J Toxicol Clin Toxicol.* 2002;40(1):3–20.
- Manyike PT, et al. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. *Clin Pharmacol Ther.* 2000;67(3):275–82.
- Forrest JAH, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. *Clin Pharmacokinet.* 1982;7(2):93–107.
- Hilmer SN, McLachlan AJ, Le Couteur DG. Clinical pharmacology in the geriatric patient. *Fundam Clin Pharmacol.* 2007;21(3):217–30.
- FDA. Pediatric science and research activities—FDA pediatric study decision tree. 2016 [cited 2018 06-02]. <https://www.fda.gov/ScienceResearch/SpecialTopics/PediatricTherapeuticsResearch/ucm106614.htm>. Accessed 10 Nov 2017.
- Manolis E, Pons G. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework. *Br J Clin Pharmacol.* 2009;68(4):493–501.
- Anderson BJ, et al. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. *Paediatr Anaesth.* 2005;15(4):282–92.
- Wynne HA, et al. The association of age and frailty with paracetamol conjugation in man. *Age Ageing.* 1990;19(6):419–24.
- Triggs EJ, et al. Pharmacokinetics in the elderly. *Eur J Clin.* 1975;8(1):55–62.
- Gainsborough N, et al. The association of age with gastric emptying. *J Age Relat Disord.* 1993;5(6):6–7.
- Rashid MU, Bateman DN. Effect of intravenous atropine on gastric emptying, paracetamol absorption, salivary flow and heart rate in young and fit elderly volunteers. *Br J Clin Pharmacol.* 1990;30(1):25–34.
- Divoll M, Greenblatt DJ, Ameer B. Effect of food on acetaminophen absorption in young and elderly subjects. *J Clin Pharmacol.* 1982;22(11–12):571–6.
- Divoll M, et al. Age does not alter acetaminophen absorption. *J Am Geriatr Soc.* 1982;30(4):240–4.

30. Divoll M, et al. Acetaminophen kinetics in the elderly. *Clin Pharmacol Ther.* 1982;31(2):151–6.
31. Bedjaoui A, et al. [Effect of age and sex on the pharmacokinetics of paracetamol] *French. Therapie.* 1984;39(4):353–9.
32. Briant RH, et al. The rate of acetaminophen metabolism in the elderly and the young. *J Am Geriatr Soc.* 1976;24(8):359–61.
33. Robertson DR, et al. The influence of levodopa on gastric emptying in healthy elderly volunteers. *Eur J Clin Pharmacol.* 1992;42(4):409–12.
34. Pujos-Guillot E, et al. Therapeutic paracetamol treatment in older persons induces dietary and metabolic modifications related to sulfur amino acids. *Age.* 2012;34(1):181–93.
35. Pickering G, et al. Acetaminophen metabolism after major surgery: a greater challenge with increasing age. *Clin Pharmacol Ther.* 2011;90(5):707–11.
36. Hagen IJ, Haram EM, Laake K. Absorption of paracetamol from suppositories in geriatric patients with fecal accumulation in the rectum. *Aging Clin Exp Res.* 1991;3(1):25–9.
37. Bannwarth B, et al. Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. *J Rheumatol.* 2001;28(1):182–4.
38. Miners JO, et al. Comparison of paracetamol metabolism in young adult and elderly males. *Eur J Clin Pharmacol.* 1988;35(2):157–60.
39. Liukas A, et al. Pharmacokinetics of intravenous paracetamol in elderly patients. *Clin Pharmacokinet.* 2011;50(2):121–9.
40. Moreau X, et al. Pharmacokinetics of acetaminophen in the cerebrospinal fluid in elderly population. *Therapie.* 1993;48(4):393–6.
41. Fulton B, James O, Rawlins MD. The influence of age on the pharmacokinetics of paracetamol [proceedings]. *Br J Clin Pharmacol.* 1979;7(4):418p.
42. Ellmers S, et al. Excretion of paracetamol in fit and frail elderly people. *J Am Geriatr Soc.* 1991;31:596–7.
43. Kamali F, Thomas SHL, Ferner RE. Paracetamol elimination in patients with non-insulin dependent diabetes mellitus. *Br J Clin Pharmacol.* 1993;35(1):58–61.
44. Greenblatt DJ, et al. Close correlation of acetaminophen clearance with that of conjugated benzodiazepines but not oxidized benzodiazepines. *Eur J Clin Pharmacol.* 1983;25(1):113–5.
45. Mitchell SJ, et al. Hepatotoxicity of therapeutic short-course paracetamol in hospital inpatients: impact of ageing and frailty. *J Clin Pharm Ther.* 2011;36(3):327–35.
46. Jahr JS, et al. Safety and efficacy of intravenous acetaminophen in the elderly after major orthopedic surgery: subset data analysis from 3, randomized, placebo-controlled trials. *Am J Ther.* 2012;19(2):66–75.
47. Alexander AM, Veitch GBA, Wood JB. Anti-rheumatic and analgesic drug usage and acute gastro-intestinal bleeding in elderly patients. *J Clin Hosp Pharm.* 1985;10(1):89–93.
48. Koppert W, et al. The effects of paracetamol and parecoxib on kidney function in elderly patients undergoing orthopedic surgery. *Anesth Analg.* 2006;103(5):1170–6.
49. Langman MJS, et al. Risks of bleeding peptic ulcer associate with individual non-steroidal anti-inflammatory drugs. *Lancet.* 1994;343(8905):1075–8.
50. Rahme E, Barkun A, Nedjar H. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. *Am J.* 2008;103(4):872–82.
51. Rahme E, Pettitt D, LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional non-steroidal antiinflammatory drugs in an elderly population. *Arthritis Rheum.* 2002;46(11):3046–54.
52. Rahme E, et al. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. *Aliment Pharmacol Ther.* 2007;26(10):1387–98.
53. Pickering G, et al. A New transmucous-buccal formulation of acetaminophen for acute traumatic pain: a non-inferiority, randomized, double-blind, clinical trial. *Pain Physician.* 2015;18(3):249–57.
54. Pickering G, et al. Buccal acetaminophen provides fast analgesia: two randomized clinical trials in healthy volunteers. *Drug Des Devel Ther.* 2014;8:1621–7.
55. Zeilmaker GA, et al. Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit; targeting postoperative, ECMO and hypothermia patients. *Expert Opin Drug Metab Toxicol.* 2018;14:1–12.
56. Gibb IA, Anderson BJ. Paracetamol (acetaminophen) pharmacodynamics: interpreting the plasma concentration. *Arch Dis Child.* 2008;93(3):241–7.
57. Allegaert K, et al. Covariates of intravenous paracetamol pharmacokinetics in adults. *BMC Anesthesiol.* 2014;14:77.
58. Van Donge T, et al. Drug metabolism in early infancy: opioids as an illustration. *Expert Opin Drug Metab Toxicol.* 2018;14(3):287–301.
59. EMA. Physical frailty: instruments for baseline characterisation of older populations in clinical trials. 2018 [cited 2018 27-02]. [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/clinical\\_general/general\\_content\\_001232.jsp&mid=WC0b01ac0580032ec4](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/clinical_general/general_content_001232.jsp&mid=WC0b01ac0580032ec4). Accessed 27 Feb 2018.
60. Mitchell SJ, Kane AE, Hilmer SN. Age-related changes in the hepatic pharmacology and toxicology of paracetamol. *Curr Gerontol Geriatr Res.* 2011;2011:624156.
61. Watkins PB, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. *JAMA.* 2006;296(1):87–93.
62. Pharmacological management of persistent pain in older persons. *Pain Med.* 2009;10(6):1062–83.
63. Abdulla A, et al. Guidance on the management of pain in older people. *Age Ageing.* 2013;42(Suppl 1):i1–57.
64. FDA. OFIRMEV. 2010. [https://www.accessdata.fda.gov/drugs\\_atfda\\_docs/label/2010/022450lbl.pdf](https://www.accessdata.fda.gov/drugs_atfda_docs/label/2010/022450lbl.pdf). Accessed 1 Mar 2018.
65. Ltd, B.M.S.P. Package Leaflet Peralgan 10 mg/mL. 2016 [cited 2018 07-02]; <https://www.medicines.org.uk/emc/files/pil.60.pdf>. Accessed 1 Mar 2018.
66. CBG-MEB. Panadol Gladde tablet, filmomhulde tabletten. 2016 [cited 2018 05/19]. <https://db.cbg-meb.nl/Bijlsluiters/h18550.pdf>. Accessed 1 Mar 2018.